Breast Cancer Treatment at CMN Hospital
Women who come to CMN Hospital for breast cancer treatment are often looking for a more comprehensive and organized approach to their care. Many arrive feeling physically exhausted, emotionally overwhelmed, and tired of managing appointments, treatments, travel, and difficult decisions while already carrying the weight of a breast cancer diagnosis.
Inside Dr. Edgar Payán’s 28-day inpatient program, care is brought together within one hospital environment. Therapies, laboratory services, meals, physician evaluations, and daily care are coordinated around the patient while she remains within the comfort and privacy of her suite throughout most of her stay.
Many women express relief once they arrive because they no longer feel responsible for carrying every detail alone. Their days become more structured, organized, and calm, allowing them to focus more fully on rest, recovery, and healing while receiving care at CMN Hospital.
Hormone-Positive Breast Cancer
Hormone-positive breast cancers, including estrogen receptor-positive (ER+) and progesterone receptor-positive (PR+) breast cancer, are among the most common breast cancer diagnoses treated at CMN Hospital. Many women initially undergo chemotherapy, radiation, surgery, hormone-blocking medications, immunotherapy, or targeted therapies before eventually searching for additional options after recurrence, progression, or physically difficult recoveries.
Over the years, more women facing advanced-stage and recurrent breast cancer continued arriving at CMN Hospital after already undergoing extensive conventional treatment. As a result, Dr. Edgar Payán’s inpatient experience naturally evolved around helping women whose bodies often felt physically exhausted, nutritionally depleted, inflamed, and weakened following prior therapies.
Inside the 28-day inpatient program, care focuses not only on treatment planning, but also on helping the body regain strength, nutritional stability, immune support, and recovery support throughout the patient’s stay. Therapies are individualized based on diagnosis, imaging, pathology, present condition, and prior treatment history.
Research involving autologous hematopoietic stem cell transplantation in advanced breast cancer has continued for decades, particularly in women with metastatic and recurrent disease following chemotherapy. Stanford University researchers published long-term findings involving women with stage IV breast cancer treated with high-dose chemotherapy followed by transplantation using highly purified autologous hematopoietic stem cells.
The Stanford researchers reported favorable long-term survival outcomes within portions of the study population and concluded that purified autologous stem-cell-supported treatment strategies in advanced breast cancer warranted continued scientific attention. At CMN Hospital, Dr. Edgar Payán incorporates autologous bone marrow stem cell therapy within individualized inpatient treatment planning for some breast cancer patients as part of a broader program focused on recovery support, immune function, nutritional stability, and helping the body regain strength following prior treatments.
Triple Negative Breast Cancer Research
Triple Negative Breast Cancer (TNBC) continues to be one of the most difficult forms of breast cancer to treat because it does not respond to hormone-blocking therapies commonly used in estrogen receptor-positive or progesterone receptor-positive breast cancers. Researchers continue searching for therapies that may help target aggressive TNBC cellular behavior more effectively.
Published laboratory research involving scorpion venom compounds and chlorotoxin has shown growing scientific interest in how venom-derived peptides may interact with breast cancer cells, including Triple Negative Breast Cancer cell lines. Researchers have studied possible effects involving apoptosis, cellular signaling, migration, invasion pathways, and tumor cell viability.
A study published within the National Institutes of Health (NIH) database reported that Rhopalurus junceus scorpion venom demonstrated significant reduction in breast cancer cell viability and induced apoptosis activity within Triple Negative Breast Cancer laboratory cell models. Additional reviews discussing chlorotoxin and venom-derived peptides have examined their interaction with pathways involving TNBC cellular migration and invasion.
Researchers have also studied chlorotoxin because of its ability to bind to certain proteins and enzymes overexpressed in aggressive tumors. Published reviews have discussed possible effects involving MMP-2 pathways, tumor invasion behavior, and metastatic signaling mechanisms connected to breast cancer progression.
At CMN Hospital, Dr. Edgar Payán incorporates blue scorpion venom within individualized treatment planning for some breast cancer patients as part of a broader inpatient program that may also include dendritic cell therapy, autologous bone marrow stem cell therapy, IV therapies, laboratory monitoring, nutritional support, and additional therapies selected based upon the patient’s diagnosis, condition, and treatment history.
Scientific References
Díaz-García et al. — Rhopalurus junceus scorpion venom induces apoptosis in breast cancer cells and reduced cell viability in Triple Negative Breast Cancer models.
Kwon et al. — Systematic review examining anticancer effects and mechanisms of scorpion venom and chlorotoxin-related peptides in breast cancer cell lines including TNBC and hormone-positive breast cancer.
Published research involving chlorotoxin has also examined interactions involving MMP-2 signaling, tumor migration pathways, and targeted tumor-binding mechanisms in aggressive cancers.
